Patents by Inventor Catherine Brenner

Catherine Brenner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
    Publication number: 20230221321
    Abstract: The invention relates to a method for identifying compounds useful for the treatment of cancer based on assessing the ability of the compound to modulate the interaction between the AIF protein and the CHCHD4 protein.
    Type: Application
    Filed: February 26, 2021
    Publication date: July 13, 2023
    Inventors: CATHERINE BRENNER, NAZANINE MODJTAHEDI
  • Use of minaprine to reduce tumor growth
    Patent number: 11517575
    Abstract: The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: December 6, 2022
    Assignee: Institut Gustave Roussy
    Inventors: Jean Luc Perfettini, Eric Deutsch, Catherine Brenner, Jean-Christophe Cintrat, Frederic Taran
  • Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy
    Patent number: 11471463
    Abstract: The present invention is drawn to the use of the compounds highlighted in Tables 1 & 2 and analogs thereof, for enhancing IR-mediated cellular cannibalism in cancer cells. Said compounds are herein called “enhancers of IR-mediated cellular cannibalism”. They can be used to enhance tumor immunogenicity and/or to induce a significant protective anticancer immune response in subjects that will receive or that have received a radiotherapy treatment. In other words, said compounds can be used to potentiate a radiotherapy treatment in a subject in need thereof. Said compounds are preferably chosen in the group consisting of: Mebhydroline 1,5-napthalene disulfonate salt, Flurbiprofen, Minaprine dihydrochloride, Myricetin, Digoxin, Digitoxin, Lanatoside, LOPA87, VP331, RN-1-026, SG6163F, VP450, and VP43.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: October 18, 2022
    Assignee: Institut Gustave Roussy
    Inventors: Jean Luc Perfettini, Eric Deutsch, Catherine Brenner, Jean-Christophe Cintrat, Frederic Taran
  • Use of Minaprine to Reduce Tumor Growth
    Publication number: 20210060029
    Abstract: The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.
    Type: Application
    Filed: January 23, 2019
    Publication date: March 4, 2021
    Applicant: Institut Gustave-Roussy
    Inventors: Jean Luc PERFETTINI, Eric DEUTSCH, Catherine BRENNER, Jean-Christophe CINTRAT, Frederic TARAN
  • Enhancers of Cellular Cannibalism for Use to Sensitize Tumors to Radiation Therapy
    Publication number: 20190358239
    Abstract: The present invention is drawn to the use of the compounds highlighted in Tables 1 & 2 and analogs thereof, for enhancing IR-mediated cellular cannibalism in cancer cells. Said compounds are herein called “enhancers of IR-mediated cellular cannibalism”. They can be used to enhance tumor immunogenicity and/or to induce a significant protective anticancer immune response in subjects that will receive or that have received a radiotherapy treatment. In other words, said compounds can be used to potentiate a radiotherapy treatment in a subject in need thereof. Said compounds are preferably chosen in the group consisting of: Mebhydroline 1,5-napthalene disulfonate salt, Flurbiprofen, Minaprine dihydrochloride, Myricetin, Digoxin, Digitoxin, Lanatoside, LOPA87, VP331, RN-1-026, SG6163F, VP450, and VP43.
    Type: Application
    Filed: January 23, 2018
    Publication date: November 28, 2019
    Applicant: Institut Gustave-Roussy
    Inventors: Jean Luc PERFETTINI, Eric DEUTSCH, Catherine BRENNER, Jean-Christophe CINTRAT, Frederic TARAN
  • Ant-ligands molecules and biological applications
    Patent number: 9657031
    Abstract: ANT-ligands having a substituted nitrogeneous heterocycle A wherein A is a substituted pyrimidinone of formula I wherein R1 is —(CH2)n-CO—OH; —(CH2)n-CO—OR; —(CH2)n-CO—NHR; —(CH2)n-CO—N(R, R?); —(CH2)n-OH; —(CH2)n-OR; —(CH2)n-OAr; —(CH2)n-C(R,R?)—(CH2)n-OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 23, 2017
    Assignees: Universite de Versailles-Saint-Quentin-en-Yvelines, Center National de la Recherche Scientifique (CNRS), Mitologics
    Inventors: Annie Borgne-Sanchez, Etienne Jacotot, Catherine Brenner
  • ANT-LIGANDS MOLECULES AND BIOLOGICAL APPLICATIONS
    Publication number: 20140350033
    Abstract: ANT-ligands having a substituted nitrogeneous heterocycle A wherein A is a substituted pyrimidinone of formula I wherein R1 is —(CH2)n-CO—OH; —(CH2)n-CO—OR; —(CH2)n-CO—NHR; —(CH2)n-CO—N(R, R?); —(CH2)n-OH; —(CH2)n-OR; —(CH2)n-OAr; —(CH2)n-C(R,R?)—(CH2)n-OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 27, 2014
    Applicants: MITOLOGICS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE VERSAILLES-SAINT QUENTIN-EN-YVELINES (UVSQ)
    Inventors: Annie BORGNE-SANCHEZ, Etienne JACOTOT, Catherine BRENNER
  • ANT-ligands molecules and biological applications
    Patent number: 8809346
    Abstract: The invention relates to molecules ANT-ligands having a substituted nitrogeneous heterocycle A wherein A is a substituted pyrazinone of formula I wherein R1 is —(CH2)n—CO—OH; —(CH2)n—CO—OR; —(CH2)n—CO—NHR; —(CH2)n—CO—N(R,R?); —(CH2)n—OH; —(CH2)n—OR; —(CH2)n—OAr; —(CH2)n—C(R,R?)—(CH2)n—OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: August 19, 2014
    Assignees: Universite de Versailles-Saint-Quentin-en-Yvelines, Center National de la Recherche Scientifique (CNRS), Mitologics
    Inventors: Annie Borgne-Sanchez, Etienne Jacotot, Catherine Brenner
  • ANT-LIGANDS MOLECULES AND BIOLOGICAL APPLICATIONS
    Publication number: 20110086865
    Abstract: The invention relates to molecules ANT-ligands having a substituted nitrogeneous heterocycle A wherein —A is a substituted pyrazinone of formula I wherein R1 is —(CH2)n —CO—OH; —(CH2)n —CO—OR; —(CH2)n —CO—NHR; —(CH2)n —CO—N(R, R?); —(CH2)n —OH; —(CH2)n —OR; —(CH2)n —OAr; —(CH2)n —C(R,R?) —(CH2)n —OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.
    Type: Application
    Filed: May 29, 2009
    Publication date: April 14, 2011
    Applicant: MITOLOGICS
    Inventors: Annie Borgne-Sanchez, Etienne Jacotot, Catherine Brenner
  • Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT)
    Patent number: 7642051
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: January 5, 2010
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator)
    Patent number: 7056735
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: June 6, 2006
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Mechanism of mitochondrial membrane permeabilization by HIV-1 VPR, mimetics of Vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of Vpr with ANT
    Publication number: 20060052285
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: July 8, 2005
    Publication date: March 9, 2006
    Applicants: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Jacotot, Guido Kroemer, Bernard Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Mechanism of mitochondrial membrane permeabilization by HIV-1 Vpr, mimetics of Vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of Vpr with ANT
    Publication number: 20040072146
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: March 10, 2003
    Publication date: April 15, 2004
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelmann, Johan Hoebeke, Catherine Brenner-Jan, Anne-Sophie Belzacq
  • Mimetics and inhibitors of the interaction between Vpr (HIV vIral protein of regulation) and ANT (mitochondrial adenine nucleotide translocator)
    Publication number: 20020068273
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: September 12, 2001
    Publication date: June 6, 2002
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jan, Anne-Sophie Belzacq